DUBLIN - Feb. 10, 2015 - The ClosureFast(TM) endovenous radiofrequency ablation catheter from Medtronic plc (MDT) is safe and effective for the treatment of chronic venous insufficiency (CVI) over ...
DUBLIN and LONDON - April 17, 2019-Medtronic plc (NYSE:MDT) today announced five-year outcomes from the VeClose Extension Study. Nick Morrison, M.D., Center for Vein Restoration, Mesa, Ariz., ...
12 month closure rates for the VenaSeal closure system comparable to radiofrequency ablation DUBLIN, Medtronic plc today announced the twelve-month results of the VeClose pivotal study, which ...
Three-Year VeClose Trial and One-Year WAVES Study Data Presented at Charing Cross DUBLIN and LONDON - April 25, 2017 - Medtronic plc (MDT) today announced three-year outcomes from the VeClose U.S.
Medical device major Medtronic plcMDT recently unveiled 12-month results from its VeClose study, validating the clinical durability of its VenaSeal closure system, at the European Venous Forum 2015 in ...
The latest data from Medtronic ($MDT) demonstrate just how wide its market reach extends. It found that a recently approved adhesive treatment for chronic venous ...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, today announced that more than 200,000 ClosureFast ® ...
September 26, 2006 -- The US Food and Drug Administration (FDA) has granted a clinical laboratory improvement amendment waiver for a portable lead test, thereby improving its availability and access, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results